Patents Assigned to ALECTOR LLC
  • Patent number: 11147249
    Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 19, 2021
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Seung-Joo Lee
  • Publication number: 20210317208
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: October 14, 2021
    Applicant: Alector LLC
    Inventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
  • Patent number: 11136390
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 11, 2016
    Date of Patent: October 5, 2021
    Assignee: ALECTOR LLC
    Inventors: Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
  • Publication number: 20210284710
    Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
    Type: Application
    Filed: November 3, 2020
    Publication date: September 16, 2021
    Applicant: Alector LLC
    Inventors: Spencer Liang, Samuel Nalle, Jeonghoon Sun, Hua Long, Rashmi Bankoti
  • Publication number: 20210277113
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRP?1 polypeptide, e.g., a human SIRP?1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 9, 2021
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Patricia Culp, Arnon Rosenthal
  • Publication number: 20210246204
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 7, 2019
    Publication date: August 12, 2021
    Applicant: Alector LLC
    Inventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
  • Patent number: 11084875
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: August 10, 2021
    Assignee: ALECTOR LLC
    Inventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
  • Publication number: 20210139581
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: May 7, 2020
    Publication date: May 13, 2021
    Applicant: ALECTOR LLC
    Inventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
  • Publication number: 20210121583
    Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.
    Type: Application
    Filed: November 3, 2020
    Publication date: April 29, 2021
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE
  • Publication number: 20210101978
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
    Type: Application
    Filed: November 30, 2020
    Publication date: April 8, 2021
    Applicant: Alector LLC
    Inventor: Arnon ROSENTHAL
  • Publication number: 20210095023
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: April 1, 2021
    Applicant: Alector LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Publication number: 20210017275
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: May 15, 2018
    Publication date: January 21, 2021
    Applicant: Alector LLC
    Inventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
  • Patent number: 10875919
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 29, 2020
    Assignee: ALECTOR LLC
    Inventor: Arnon Rosenthal
  • Publication number: 20200392229
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 17, 2020
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
  • Patent number: 10849992
    Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: December 1, 2020
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Tina Schwabe
  • Patent number: 10800844
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 13, 2020
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Publication number: 20200317776
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 8, 2020
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
  • Publication number: 20200277374
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: September 3, 2020
    Applicant: Alector LLC
    Inventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
  • Publication number: 20200223928
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Applicant: Alector LLC
    Inventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS
  • Patent number: 10711062
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: July 14, 2020
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal